Click Here For COVID-19 (Coronavirus) Studies

Trials Offered by a Specific Doctor

Magdalena Sobieszczyk, MD, MPH
Dr. Magdalena Sobieszczyk is the PI of the NIH-funded Columbia HVTN and ACTG Clinical Research Site. Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP). Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP; and evaluating host factors influencing immunologic and virologic course of HIV disease and response to vaccination in study participants. She has been involved in the development and implementation of several international and national HIV prevention protocols and is the co-chair of phase 2b HIV vaccine protocol to determine the safety and efficacy of the DNA prime-Ad5 boost vaccine regimen in individuals at risk of HIV infection (HVTN 505).

Her research with HIV infected individuals includes investigating HIV testing and linkage to care in the predominantly Latino communities of northern Manhattan. This also includes describing the prevalence of metabolic and renal abnormalities in this population and in South African cohorts.

Dr. Sobieszczyk is also a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled “Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection” (Salim Abdool Karim, PI).

Clinical Studies Managed By Dr. Sobieszczyk:
More InfoTitleSponsorIRB Number
Details[CLOSED] A phase 1/2a HIV vaccine study designed to test the safety and immune responses of different vaccine combinations among HIV adults.NIHAAAQ9402
DetailsHIV Prevention StudyNIHAAAA6427
DetailsA protocol to find out if people are eligible for any of the HIV prevention studies we are conducting and currently enrolling people into.National Institute of HealthAAAA6427
Details[CLOSED] Antibodies for HIV PreventionNIHAAAR7055
Details[CLOSED] Antibodies against HIVNIHAAAR9464
Details[CLOSED] HIV prevention study: HVTN 120NIHAAAR6422
Details[CLOSED] Bispecific Antibody Study: 18-60-year-old, Healthy & HIV-Negative VolunteersAaron Diamond AIDS Research CenterAAAS1239
Details[CLOSED] Bispecific Antibody Study for 18-60-year-old People Who Live With HIV/AIDSAaron Diamond AIDS Research CenterAAAS1239
DetailsHIV Vaccine Study Among 18-60 year-old Sexually Active Men or Transgender IndividualsNational Institutes of HealthAAAS5793
Details[CLOSED] A Study Among 18-50 Year Old People Who Do NOT Have HIV Comparing an Antibody in Combination with 3 Different Antibodies (CUIMC)NIH, NIAID, DAIDSAAAS4038
Details[CLOSED] Study of Sarilumab for Patients Hospitalized with COVID-19RegeneronAAAS9615
DetailsARMOR Study: A Study to Follow COVID-19 Antibodies Over TimeColumbia UniversityAAAS9998
DetailsA study to describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19NIHAAAT0172
DetailsScreening for COVID-19 vaccine, prevention and treatment research studiesNational Institute of Allergy and Infectious DiseasesAAAT2629